Printer Friendly

Androclus Therapeutics Announces Formation Of Clinical Advisory Board.

SAN DIEGO & MILAN, Italy -- Androclus Therapeutics announced today the formation of a Clinical Advisory Board (CAB) for Neurology, which has been assembled to guide the company in the clinical development of therapeutics for autoimmune diseases such as multiple sclerosis.

Androclus' clinical drug candidate for the treatment of multiple sclerosis, AT-008, is an orally administered immunomodulatory peptide, currently undergoing preclinical testing.

The Clinical Advisory Board, composed of leading experts in the field of Multiple Sclerosis and Immunology, will be instrumental in defining Androclus' clinical development strategy and in designing and implementing upcoming clinical trials of AT-008 for the treatment of multiple sclerosis.

The Androclus Therapeutics Clinical Advisory Board is now composed of:

--David Hafler, M.D. is Professor of Neurology and Director of the Laboratory of Molecular Immunology at the Harvard Medical School. He also is a physician at the Brigham and Women's Hospital. Dr. Hafler is founder and co-chair of Federation of Clinical Immunology Societies and a member of editorial boards of Journal of Neuroimmunology and Journal of Clinical Investigation.

--Robert M. Herndon, M.D. is Professor of Neurology at the University of Mississippi and Editor of the International Journal of MS Care. He is past president of the Consortium of MS Centers and a member of the Medical Advisory Board of the National Multiple Sclerosis Society.

--Antonio Uccelli, M.D. is Assistant Professor at the Department of Neurosciences, Ophthalmology and Genetics, University of Genoa, Italy. He is also a faculty member of the Multiple Sclerosis Clinic of the University of Genoa. Dr. Uccelli is a member of the Executive Board of the Italian Society of Neuroimmunology and is the Secretary of the Scientific Committee of the Italian Multiple Sclerosis Society.

"With the expected initiation of clinical trials for our drug candidate for multiple sclerosis AT-008 approaching in 2005, I am very pleased that we have been able to attract individuals with strong reputations and the depth of experience in multiple sclerosis and immunology," said Igor Bilinsky, Ph.D., Androclus' Chief Operating Officer. "We look forward to a long and successful relationship with our new Advisors."

About Androclus Therapeutics

Androclus Therapeutics is a private clinical stage biotechnology company with a mission to discover and develop novel therapeutics and technologies for the treatment of diseases involving the immune system, such as rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Androclus' leading drug candidate, AT-001 (dnaJP1), is an orally administered peptide for the treatment of rheumatoid arthritis, currently in a Phase II clinical trial. A previously completed Phase I/IIa trial of AT-001 demonstrated safety, biological efficacy and provided evidence of clinical efficacy. The approach is based on restoration of regulatory Tcell activity that is impaired in patients with autoimmune diseases. Androclus has partnered AT-001 with a large biotechnology company. Building on the success of AT-001, Androclus is now developing orally administered therapeutic peptides for the treatment of multiple sclerosis and inflammatory bowel disease, currently in the preclinical stage. For more information, visit Androclus' web site at
COPYRIGHT 2004 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Nov 2, 2004
Previous Article:T-3 Energy Services Inc. Announces Design and Manufacture of T-3 Model 6011 Ram Blowout Preventer.
Next Article:Advanced Fiber Technologies (AFT) Income Fund Reports Third Quarter Results.

Related Articles
Androclus Therapeutics Announces Publication of Phase I/IIa Rheumatoid Arthritis Clinical Trial Results.
Androclus Therapeutics, Inc. Is Granted Patent For Artificial Antigen Presenting Cells.
Androclus Therapeutics to Present at Windhover Information's ``The Start-Up Forum 2005''.
Androclus Therapeutics Announces Completion of First Institutional Financing.
Androclus Therapeutics Announces Publication in Lancet of Results of Tolerogenic Immune Responses to hsp60 Epitopes in Juvenile Idiopathic Arthritis.
Androclus Therapeutics Reports Completion Of A Phase 2 Clinical Trial Of AT-001 (DnaJP1) In Patients With Rheumatoid Arthritis.
Androclus Therapeutics Announces Patent For Heat Shock Protein Derived Peptides Licensed From University Of California.
Point Therapeutics Announces Additions to Scientific and Clinical Advisory Boards.
ChemGenex Announces Appointment of Two Experienced Non-Executive Directors.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters